Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Other Guidelines

Pseudomonas aeruginosa infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis

  • Read more about Pseudomonas aeruginosa infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis

What do different bacteria together do to the lung epithelium in Cystic Fibrosis

  • Read more about What do different bacteria together do to the lung epithelium in Cystic Fibrosis

Aquagenic wrinkling in children under two years of age: Could this be a potential clinical referral tool for cystic fibrosis among non-screened populations?

  • Read more about Aquagenic wrinkling in children under two years of age: Could this be a potential clinical referral tool for cystic fibrosis among non-screened populations?

SARS-CoV2 infection in CF patient colonized by Burkholderia cenocepacia

  • Read more about SARS-CoV2 infection in CF patient colonized by Burkholderia cenocepacia

Does Using Home Spirometry Lower Healthcare Costs of Care for people with cystic fibrosis?

  • Read more about Does Using Home Spirometry Lower Healthcare Costs of Care for people with cystic fibrosis?

Risk factors for joint inflammation and joint pain in cystic fibrosis

  • Read more about Risk factors for joint inflammation and joint pain in cystic fibrosis

The effect of lumacaftor-ivacaftor on mucus clearance

  • Read more about The effect of lumacaftor-ivacaftor on mucus clearance

Evaluating Pulmonary Exacerbation Treatment Differences in Women and Men with CF

  • Read more about Evaluating Pulmonary Exacerbation Treatment Differences in Women and Men with CF

Appearance and behaviour of methicillin resistant Staphylococcus aureus (MRSA) from early and chronic infection in cystic fibrosis (CF)

  • Read more about Appearance and behaviour of methicillin resistant Staphylococcus aureus (MRSA) from early and chronic infection in cystic fibrosis (CF)

Liver toxicity with triple therapy in cystic fibrosis: when it is worth taking the risk.

  • Read more about Liver toxicity with triple therapy in cystic fibrosis: when it is worth taking the risk.
  • first
  • previous
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)